Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 7Sarcoma 1CNS 1

Conditions

Glioblastoma 8Gliosarcoma 7Brain Neoplasms 5Central Nervous System Neoplasms 4Osteosarcoma 2Oligodendroglioma 2Glioma 2Astrocytoma 2Untreated Childhood Anaplastic Astrocytoma 1Sarcoma, Synovial 1Sarcoma 1Rhabdomyosarcoma 1Prostatic Neoplasms 1Neuroblastoma 1Neoplasm Metastasis 1Meningioma 1Glioma, Subependymal 1

Interventions

Gemcitabine 4pembrolizumab 3Docetaxel 3Cryosurgery 3Biopsy 3eribulin 2durvalumab 2balstilimab 2atezolizumab 2aflibercept 2Zoledronic Acid 2Trastuzumab 2Taxes 2Specimen Handling 2Radiotherapy 2Radiosurgery 2Radiation 2Nivolumab 2Magnetic Resonance Spectroscopy 2Letrozole 2Irinotecan 2Gene Expression Profiling 2Fulvestrant 2Cisplatin 2Blood Specimen Collection 2Bevacizumab 2130-nm albumin-bound paclitaxel 2trifluridine tipiracil drug combination 1tremelimumab 1trastuzumab deruxtecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × Gefitinib × Sarcoma × Clear all
NCT00085566 2016-01-20

Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer

Memorial Sloan Kettering Cancer Center

Phase 1/2 Completed
61 enrolled 8 charts
CNSGenitourinarySarcoma

Brain Neoplasms, Glioblastoma, Prostatic Neoplasms, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡